

# Lourdes Mengual

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1157923/publications.pdf>

Version: 2024-02-01

53  
papers

2,040  
citations

279798

23  
h-index

233421

45  
g-index

57  
all docs

57  
docs citations

57  
times ranked

3321  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 70-83.	5.4	5
2	Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution. <i>Prostate</i> , 2022, 82, 1331-1337.	2.3	2
3	Prognostic classifier for predicting biochemical recurrence in localized prostate cancer patients after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 493.e17-493.e25.	1.6	4
4	Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication. <i>Scientific Reports</i> , 2021, 11, 6132.	3.3	7
5	Semen sampling as a simple, noninvasive surrogate for prostate health screening. <i>Systems Biology in Reproductive Medicine</i> , 2021, 67, 354-365.	2.1	3
6	Clinicopathological and Molecular Prognostic Classifier for Intermediate/High-Risk Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 6338.	3.7	2
7	Urine Gene Expression Profiles in Bladder Pain Syndrome Patients Treated with Triamcinolone. <i>European Urology Focus</i> , 2020, 6, 390-396.	3.1	3
8	Urine cytology suspicious for urothelial carcinoma: Prospective follow-up of cases using cytology and urine biomarker-based ancillary techniques. <i>Cancer Cytopathology</i> , 2020, 128, 460-469.	2.4	5
9	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 203.	4.1	15
10	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>Journal of Urology</i> , 2020, 203, 283-291.	0.4	10
11	Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. <i>Translational Research</i> , 2019, 208, 73-84.	5.0	5
12	Multiple immunofluorescence assay identifies upregulation of Active $\beta$ -catenin in prostate cancer. <i>BMC Research Notes</i> , 2019, 12, 68.	1.4	1
13	Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study. <i>Environment International</i> , 2019, 122, 389-399.	10.0	28
14	Re: Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>European Urology</i> , 2018, 74, 397.	1.9	1
15	Mediterranean Dietary Pattern is Associated with Low Risk of Aggressive Prostate Cancer: MCC-Spain Study. <i>Journal of Urology</i> , 2018, 199, 430-437.	0.4	89
16	Quantitative RNA Analysis from Urine Using Real Time PCR. <i>Methods in Molecular Biology</i> , 2018, 1655, 227-237.	0.9	6
17	Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study. <i>Journal of Cancer</i> , 2018, 9, 3208-3215.	2.5	0
18	Urine cell-based DNA methylation classifier for monitoring bladder cancer. <i>Clinical Epigenetics</i> , 2018, 10, 71.	4.1	39

#	ARTICLE	IF	CITATIONS
19	Prognostic value of circulating microRNAs in upper tract urinary carcinoma. <i>Oncotarget</i> , 2018, 9, 16691-16700.	1.8	16
20	Urinary cell microRNA-based prognostic classifier for non-muscle invasive bladder cancer. <i>Oncotarget</i> , 2017, 8, 18238-18247.	1.8	22
21	Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study. <i>Oncotarget</i> , 2017, 8, 51522-51529.	1.8	8
22	Perinatal and childhood factors and risk of prostate cancer in adulthood: MCC-Spain case-control study. <i>Cancer Epidemiology</i> , 2016, 43, 49-55.	1.9	8
23	Reply to letter commenting on: A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>European Journal of Cancer</i> , 2016, 68, 198.	2.8	0
24	A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>European Journal of Cancer</i> , 2016, 64, 127-136.	2.8	67
25	Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers. <i>BMC Cancer</i> , 2016, 16, 76.	2.6	22
26	Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. <i>European Journal of Cancer</i> , 2016, 54, 131-138.	2.8	32
27	Prognostic value of <sc>microRNA</sc> expression pattern in upper tract urothelial carcinoma. <i>BJU International</i> , 2014, 113, 813-821.	2.5	29
28	SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. <i>Molecular Cancer</i> , 2014, 13, 237.	19.2	60
29	Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. <i>Clinica Chimica Acta</i> , 2014, 435, 53-58.	1.1	13
30	Validation Study of a Noninvasive Urine Test for Diagnosis and Prognosis Assessment of Bladder Cancer: Evidence for Improved Models. <i>Journal of Urology</i> , 2014, 191, 261-269.	0.4	30
31	Identification of blood serum microRNAs associated with idiopathic and <i>LRRK2</i> Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2014, 92, 1071-1077.	2.9	122
32	Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. <i>BMC Cancer</i> , 2014, 14, 86.	2.6	19
33	Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1270-1284.	4.1	131
34	Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1340-1345.	2.5	57
35	Multiplex Protein Signature for the Detection of Bladder Cancer in Voided Urine Samples. <i>Journal of Urology</i> , 2013, 190, 2257-2262.	0.4	42
36	Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. <i>BMC Urology</i> , 2013, 13, 42.	1.4	26

#	ARTICLE	IF	CITATIONS
37	Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	5.1	88
38	Utility of Urothelial mRNA Markers in Blood for Staging and Monitoring Bladder Cancer. <i>Urology</i> , 2012, 79, 240.e9-240.e15.	1.0	17
39	Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?. <i>BJU International</i> , 2012, 110, 1310-1316.	2.5	21
40	MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review. <i>European Urology</i> , 2011, 59, 671-681.	1.9	401
41	Molecular characterization of upper urinary tract tumours. <i>BJU International</i> , 2010, 106, 868-872.	2.5	20
42	Gene Expression Signature in Urine for Diagnosing and Assessing Aggressiveness of Bladder Urothelial Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 2624-2633.	7.0	70
43	HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. <i>Anticancer Research</i> , 2010, 30, 2439-45.	1.1	9
44	DNA Microarray Expression Profiling of Bladder Cancer Allows Identification of Noninvasive Diagnostic Markers. <i>Journal of Urology</i> , 2009, 182, 741-748.	0.4	65
45	Multiplex preamplification of specific cDNA targets prior to gene expression analysis by TaqMan Arrays. <i>BMC Research Notes</i> , 2008, 1, 21.	1.4	31
46	Molecular Lymph Node Staging in Bladder Urothelial Carcinoma: Impact on Survival. <i>European Urology</i> , 2008, 54, 1363-1372.	1.9	40
47	Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer. <i>Cancer Genetics and Cytogenetics</i> , 2007, 173, 131-135.	1.0	31
48	Utility of Fluorescence In Situ Hybridization as a Non-invasive Technique in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma. <i>European Urology</i> , 2007, 51, 409-415.	1.9	73
49	Clinical Utility of Fluorescent in situ Hybridization for the Surveillance of Bladder Cancer Patients Treated with Bacillus Calmette-Guérin Therapy. <i>European Urology</i> , 2007, 52, 752-759.	1.9	53
50	Partially Degraded RNA from Bladder Washing is a Suitable Sample for Studying Gene Expression Profiles in Bladder Cancer. <i>European Urology</i> , 2006, 50, 1347-1356.	1.9	19
51	Fluorescence in situ hybridization analysis of matched primary tumour and lymph-node metastasis of D1 (pT2-3pN1M0) prostate cancer. <i>BJU International</i> , 2004, 94, 407-411.	2.5	7
52	Chromosomal High-Polysomies Predict Tumour Progression in T1 Transitional Cell Carcinoma of the Bladder. <i>European Urology</i> , 2004, 45, 593-599.	1.9	11
53	Marked Differences in Protamine Content and P1/P2 Ratios in Sperm Cells From Percoll Fractions Between Patients and Controls. <i>Journal of Andrology</i> , 2003, 24, 438-447.	2.0	154